Osteoporosis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Osteoporosis – Pipeline Review, H2 2017’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoporosis

The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects

The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteoporosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abreos Biosciences Inc

Alize Pharma SAS

Alvogen Korea Co Ltd

Amgen Inc

Amura Holdings Ltd

BiologicsMD Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cellmid Ltd

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Corium International Inc

Critical Pharmaceuticals Ltd

Daiichi Sankyo Co Ltd

ElexoPharm GmbH

EndoCeutics Inc

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Gador SA

GL Pharm Tech Corp

Hanmi Pharmaceuticals Co Ltd

Haoma Medica Ltd

Immunovo BV

Immunwork Inc

Intas Pharmaceuticals Ltd

Ipsen SA

Kaken Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

mAbxience SA

Merck & Co Inc

Mereo Biopharma Group Plc

NIBEC

Omeros Corp

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

R Pharm

Ribomic Inc

Sermonix Pharmaceuticals LLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shin Poong PharmCo Ltd

Sinil Pharmaceutical Co Ltd

Stelis Biopharma Pvt Ltd

Sumitomo Dainippon Pharma Co Ltd

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

Viking Therapeutics Inc

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Osteoporosis - Overview 6

Osteoporosis - Therapeutics Development 7

Osteoporosis - Therapeutics Assessment 24

Osteoporosis - Companies Involved in Therapeutics Development 34

Osteoporosis - Drug Profiles 59

Osteoporosis - Dormant Projects 226

Osteoporosis - Discontinued Products 234

Osteoporosis - Product Development Milestones 236

Appendix 249

List of Tables

List of Tables

Number of Products under Development for Osteoporosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Osteoporosis – Pipeline by Abreos Biosciences Inc, H2 2017

Osteoporosis – Pipeline by Alize Pharma SAS, H2 2017

Osteoporosis – Pipeline by Alvogen Korea Co Ltd, H2 2017

Osteoporosis – Pipeline by Amgen Inc, H2 2017

Osteoporosis – Pipeline by Amura Holdings Ltd, H2 2017

Osteoporosis – Pipeline by BiologicsMD Inc, H2 2017

Osteoporosis – Pipeline by Bone Biologics Corp, H2 2017

Osteoporosis – Pipeline by Bristol-Myers Squibb Co, H2 2017

Osteoporosis – Pipeline by Cadila Healthcare Ltd, H2 2017

Osteoporosis – Pipeline by Cellmid Ltd, H2 2017

Osteoporosis – Pipeline by ChoDang Pharm Co Ltd, H2 2017

Osteoporosis – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Osteoporosis – Pipeline by Corium International Inc, H2 2017

Osteoporosis – Pipeline by Critical Pharmaceuticals Ltd, H2 2017

Osteoporosis – Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Osteoporosis – Pipeline by ElexoPharm GmbH, H2 2017

Osteoporosis – Pipeline by EndoCeutics Inc, H2 2017

Osteoporosis – Pipeline by Entera Bio Ltd, H2 2017

Osteoporosis – Pipeline by Enteris BioPharma Inc, H2 2017

Osteoporosis – Pipeline by Enzene Biosciences Ltd, H2 2017

Osteoporosis – Pipeline by Enzo Biochem Inc, H2 2017

Osteoporosis – Pipeline by Evgen Pharma Plc, H2 2017

Osteoporosis – Pipeline by Gador SA, H2 2017

Osteoporosis – Pipeline by GL Pharm Tech Corp, H2 2017

Osteoporosis – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Osteoporosis – Pipeline by Haoma Medica Ltd, H2 2017

Osteoporosis – Pipeline by Immunovo BV, H2 2017

Osteoporosis – Pipeline by Immunwork Inc, H2 2017

Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Osteoporosis – Pipeline by Ipsen SA, H2 2017

Osteoporosis – Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017

Osteoporosis – Pipeline by Lead Discovery Center GmbH, H2 2017

Osteoporosis – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017

Osteoporosis – Pipeline by Lupin Ltd, H2 2017

Osteoporosis – Pipeline by Luye Pharma Group Ltd, H2 2017

Osteoporosis – Pipeline by mAbxience SA, H2 2017

Osteoporosis – Pipeline by Merck & Co Inc, H2 2017

Osteoporosis – Pipeline by Mereo Biopharma Group Plc, H2 2017

Osteoporosis – Pipeline by NIBEC, H2 2017

Osteoporosis – Pipeline by Omeros Corp, H2 2017

Osteoporosis – Pipeline by Oncobiologics Inc, H2 2017

Osteoporosis – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017

Osteoporosis – Pipeline by Pfenex Inc, H2 2017

Osteoporosis – Pipeline by PhytoHealth Corp, H2 2017

Osteoporosis – Pipeline by R Pharm, H2 2017

Osteoporosis – Pipeline by Ribomic Inc, H2 2017

Osteoporosis – Pipeline by Sermonix Pharmaceuticals LLC, H2 2017

Osteoporosis – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017

Osteoporosis – Pipeline by Shin Poong PharmCo Ltd, H2 2017

Osteoporosis – Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Osteoporosis – Pipeline by Stelis Biopharma Pvt Ltd, H2 2017

Osteoporosis – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Osteoporosis – Pipeline by Terpenoid Therapeutics Inc, H2 2017

Osteoporosis – Pipeline by TSH Biopharm Corporation Ltd, H2 2017

Osteoporosis – Pipeline by Uni-Bio Science Group Ltd, H2 2017

Osteoporosis – Pipeline by Viking Therapeutics Inc, H2 2017

Osteoporosis – Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2017

Osteoporosis – Pipeline by Yooyoung Pharm Co Ltd, H2 2017

Osteoporosis – Dormant Projects, H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..2), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..3), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..4), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..5), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..6), H2 2017

Osteoporosis – Dormant Projects, H2 2017 (Contd..7), H2 2017

Osteoporosis – Discontinued Products, H2 2017

Osteoporosis – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Osteoporosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports